A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

NCT02900664 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

283

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma

Interventions

BIOLOGICAL: PDR001
BIOLOGICAL: ACZ885
BIOLOGICAL: CJM112
DRUG: TMT212
DRUG: EGF816

Sponsor

Novartis Pharmaceuticals